Is venlafaxine an appropriate treatment for dizziness?

Venlafaxine is NOT appropriate for treating dizziness as a primary symptom

Venlafaxine does not treat dizziness—it causes it. Dizziness is a well-documented adverse effect of venlafaxine, occurring in 19% of patients (compared to 7% with placebo), with dose-dependent increases 1. The medication is contraindicated as a vestibular suppressant and has no role in managing benign paroxysmal positional vertigo (BPPV) or other primary vestibular disorders 2.

When Venlafaxine May Be Considered for Specific Vestibular Conditions

The only scenario where venlafaxine has evidence for dizziness-related conditions is vestibular migraine (VM) and persistent postural-perceptual dizziness (PPPD)—not dizziness itself.

Vestibular Migraine

• Venlafaxine showed equal efficacy to propranolol in reducing vertigo attacks (from 12.2 to 2.6 attacks), Dizziness Handicap Inventory scores (from 50.9 to 19.9), and vertigo severity scores 3
• Consider venlafaxine specifically for VM patients with:
  • Comorbid anxiety or depression (venlafaxine reduced Beck Depression Inventory scores, unlike propranolol) 3
  • Visually induced dizziness
  • PPPD overlap features 4
  • Marked emotional/functional impairment 4

Persistent Postural-Perceptual Dizziness (PPPD)

• Venlafaxine provided ≥50% symptom improvement in 80% (8/10) of PPPD patients 5
• PPPD is characterized by chronic (≥3 months) non-vertiginous dizziness, unsteadiness, or non-spinning vertigo exacerbated by upright posture, active/passive motion, and visual stimuli
• This is a distinct diagnosis from simple "dizziness"

Critical Distinctions

You must differentiate:

1. Primary vestibular disorders (BPPV, Meniere's disease, vestibular neuritis): Venlafaxine is NOT indicated and may worsen symptoms through its adverse effects 2

2. Vestibular migraine: Venlafaxine is a reasonable prophylactic option, particularly with psychiatric comorbidity 3, 4

3. PPPD: Venlafaxine shows specific efficacy 5

4. Neuropathic pain with dizziness: Venlafaxine treats the pain, not the dizziness. The dizziness is a dose-dependent adverse effect requiring slow titration 6

Adverse Effect Profile

Dizziness occurs in 19-23.9% of venlafaxine patients (dose-dependent: 19.1% at 75mg, 22.5% at 225mg, 23.9% at 375mg daily) versus 4.3-7% with placebo 1. This is a treatment-limiting adverse effect causing discontinuation in 3% of patients 1.

Additional vestibular-relevant adverse effects include:

• Vertigo (documented in discontinuation syndrome) 1
• Impaired coordination and balance 1
• Somnolence (23% vs 9% placebo) 1
• Confusion (2% vs 1% placebo) 1

Common Clinical Pitfall

Do not prescribe venlafaxine for undifferentiated "dizziness." The term "dizziness" encompasses vertigo, disequilibrium, presyncope, and lightheadedness 7. Venlafaxine has no role in treating these symptoms directly and will likely worsen them through adverse effects.

If considering venlafaxine for a patient with dizziness:

• Confirm the diagnosis is vestibular migraine or PPPD (not BPPV or other vestibular disorders)
• Assess for comorbid anxiety/depression that would benefit from SNRI therapy
• Start low (37.5mg daily) and titrate slowly to minimize dizziness adverse effects 6
• Monitor blood pressure (can cause hypertension) 6
• Taper gradually when discontinuing to avoid withdrawal syndrome including vertigo 1